logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
10/09/2025
Morgan Stanley CEO Ted Pick: The independence of the Federal Reserve in setting monetary policy is "sacrosanct and inviolable".
Latest
2 m ago
According to AI Express, Huayuan Securities released a research report on September 8, giving a "buy" rating to Wanyuan Tong (920060.SH). The rating reasons mainly include: 1) The continuous prosperity of double-sided and multi-layer boards driven by automotive electronics, consumer electronics, and AI servers, with significant breakthroughs in overseas business; 2) Focus on high-potential incremental applications such as optical modules, server BBU, and HDI boards, with the newly established Thai subsidiary expected to increase production capacity by 4 million square meters. (Daily Economic News)
2 m ago
The yield on Japanese government bonds with a 5-year term increased by 2.5 basis points to 1.120%.
2 m ago
According to the AI fast news of Every Economics, on September 9th, Shanxi Securities released a research report giving Huayang Shares (600348.SH) a "buy" rating. The rating reasons mainly include: 1) coal volume growth and price reduction in the first half of the year; 2) continued progress of new energy and new materials projects; 3) incremental expectations overlaid with the acquisition of exploration rights, ensuring the company's coal business continuity. (Daily Economic News)
2 m ago
Every AI Express, Shanxi Securities released a research report on September 9, giving Jin Coal Industry (601001.SH) a "hold" rating. The main reasons for the rating include: 1) improvement in coal production and sales in the second quarter of the company; 2) promoting the exploration right of Panjiayao mine and the injection of related assets, with a designed production capacity of 10 million tons per year. (Daily Economic News)
2 m ago
Bo Wang Pharmaceuticals: The innovative drug BW-20507 for the treatment of chronic hepatitis B has completed Phase II clinical trials with the first patient receiving the medication.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.